Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer

Abstract

Objective: To investigate whether LY01008, a locally developed bevacizumab biosimilar agent, is appropriate for widespread use among Chinese advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC) patients, our current study was designed to evaluate the cost-effectiveness of first-line LY01008 combined with platinum-doublet chemotherapy versus chemotherapy alone from the perspective of the Chinese healthcare system.Material and Methods: This economic evaluation designed a Markov model to compare the healthcare cost and quality-adjusted life-year (QALY) of first-line LY01008 combined with chemotherapy versus first-line chemotherapy. Transition probabilities, including disease progression, survival, and adverse event (AE)-related discontinuation of first-line treatment, were estimated using data from the clinical trials. Costs and health utilities were derived from local databases, hospitals, and published literature. Our base case analysis and scenario analysis focused on the cost-effectiveness of chemotherapy combined with a clinical trial dosage (15 mg/kg every 3-week cycle) and a real-world dosage (7.5 mg/kg every 3-week cycle) of LY01008, respectively.Results: In the base case analysis, first-line LY01008 combined with chemotherapy was associated with an increase of 0.48 QALYs in effectiveness and an increase of CNY 189,988 (US$ 26,240) in healthcare costs compared with first-line chemotherapy, resulting an incremental cost-effectiveness ratio (ICER) of CNY 375,425 (US$ 54,430)/QALY. In the scenario analysis, first-line LY01008 combined with chemotherapy was associated with a mean healthcare cost of CNY 265,060 (US$ 38,429), resulting an ICER of CNY 221,579 (US$ 32,125/QALY) between first-line LY01008 combined with chemotherapy versus first-line chemotherapy. The parameters that determine the cost of LY01008 have the greatest impact on the cost-effectiveness results.Conclusion: From the perspective of the Chinese healthcare system, first-line LY01008 at a real-world dosage combined with chemotherapy is likely to represent a cost-effective strategy compared with first-line chemotherapy alone for Chinese advanced or recurrent nonsquamous NSCLC patients.

Cost‐effectiveness analysis of tislelizumab in combination with chemotherapy for the first‐line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China

“…The dose was based on the RATIONALE‐309 trail. The patient's weight was assumed to be 65 kg and the body surface area was assumed to be 1.72 m 2 in the base case 35 . The drug costs per cycle were estimated by multiplying the unit price of the drug by the dose administered.…”

“…The patient's weight was assumed to be 65 kg and the body surface area was assumed to be 1.72 m 2 in the base case. 35 The drug costs per cycle were estimated by multiplying the unit price of the drug by the dose administered. The drug price for tislelizumab was the most latest negotiated price from the National Health Insurance Agency (NHIA) of China in 2021.…”

Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China

“…21 To calculate the dosages of etoposide and carboplatin, we assumed that the model patients have a mean body surface area of 1.72 m 2 and a mean creatinine clearance rate of 70mL/ min. 22 The treatment costs of all grade III/IV AEs were included in the model, and these AEs costs were estimated locally S3). Other direct costs such as routine follow-up costs, subsequent therapy costs, best supportive care costs and end-of-life care costs that were derived from previous literature were also considered in the model.…”

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study

“…However, no clinical data has verified the efficacy and safety of this biosimilar in clinical application. Existing trials ( 15 – 17 ) have excluded patients receiving previous treatment, patients receiving combination with targeted therapy or immunotherapy, patients with brain metastases, patients with rare genetic mutations (such as EML4-ALK rearrangement), and patients with Eastern Cooperative Oncology Group (ECOG) scores greater than 2. The efficacy and safety of bevacizumab biosimilar have no concensus in these populations.…”